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INTRODUCTION
Ubiquitination and sumoylation are two important post-
translationalmodiﬁcationsthatplaypivotal rolesinsignalingreg-
ulation, protein trafﬁcking, protein stability, and transcriptional
regulation, ultimately regulating a plethora of biological pro-
cesses such as cell survival, cell migration, DNA damage response
(DDR), neurodegeneration, and cancer. Although ubiquitination
is traditionally viewed as a critical mark targeting proteins for
proteasome-dependent degradation, recent studies have revealed
that it also has non-proteolytic functions. In contrast, sumoyla-
tion is long thought not to target proteins for degradation, but
accumulating evidence suggestst h a ti tc a ns e r v ea sap r i m i n g
pre-requisite forubiquitination,therebyinducingproteinubiqui-
tination and degradation. Thus, there is an important cross-talk
between sumoylation and ubiquitination in determining protein
fate. Deregulation in these two processes may cause aberrant
activity of proteins and in turn contributes to cancer develop-
ment. In this Research Topic, we assembled 10 review articles to
discuss the role of these two post-translational modiﬁcations in
regulating diverse signal transduction pathways, thereby provid-
ing novel insights in unraveling the puzzle as to how they may
regulate cancer progression.
The ubiquitin-proteasome system has been recently charac-
terized as a major regulatory mechanism for ensuring ordered
and coordinated cell cycle progression by selective degradation
of key cell cycle regulators. Two related, multi-subunit E3 ubiq-
uitin ligase enzymes, the Anaphase Promoting Complex (APC)
and the Skp1-Cullin1-F-box complex (SCF) are thought to be the
majordriving forces governingcell cycleprogression. Nagi Ayad’s
group discussed the important physiological functions of APC/C
as well as the upstream signaling pathway that governs the timely
regulation of APC/C. Given the critical role of APC/C in cell pro-
liferation and development, they also illustrated the emerging
contribution of APC/C in tumorigenesis and proposed APC/C
intervention as a potential anti-cancer therapeutic approach.
Among the SCF-type of E3 ubiquitin ligases, SCFSkp2 is one
of the most well-studied E3 ligases and Skp2 overexpression is
frequently observed in various types of human cancers including
breast cancer. The Wei group recently summarized the oncogenic
role of Skp2 in breast cancer development. The interplay between
Skp2 and other major signaling pathways as well as the recent
advances in identifying Skp2 downstream substrates were also
discussed. Lastly, they proposed speciﬁc Skp2 inhibitors as novel
anti-breast cancer agents.
Unlike Skp2, VHL forms a distinct type of E3 ligase by asso-
ciating with Elongin B, Elongin C, and Cullin 2. The Yang
group discussed the important role of VHL in hypoxia sensing
and kidney disease development by targeting HIF for ubiquiti-
nation and destruction in a hydroxylation-dependent manner.
They also summarized the recent advances in understanding the
tumor suppressor role of VHL independent of HIF. The identi-
ﬁcation of novel VHL substrates including PKC and EGFR and
their relevance to signaling and cancer development were also
discussed.
In addition to associating with VHL, the Elongin B/C com-
plex can also interact with the SOCS box-containing proteins
and Cullin 2 or Cullin 5 to form distinct functional E3 ubiq-
uitin ligases. The Takumi Kamura group contributed a com-
prehensive review that described the recent advances in further
characterizing the assembly as well as the physiological func-
tions of the Elongin B/C-containing E3 ligases, which are further
divided into the Cullin 2-type and the Cullin 5-type. They also
summarized the newly identiﬁed downstream substrates, which
provided an important insight into the critical roles of Elongin
B/C-containing E3 ligases in regulating a variety of cellular
functions.
The Pengbo Zhou group summarized the recent progress
in functional analysis of another major class of E3 ubiqutin
ligases, the Cullin 4-containing (CRL4) family of ligases. In
this review, the authors updated the recent understanding of
the two Cullin 4 family members, Cullin 4A and Cullin 4B
in human cancer and neuronal disease development. In addi-
tion, the recent advances in identifying novel substrates for
various Cullin 4-containing E3 ligases that typically associate
with a speciﬁc DDB1-Cullin 4 associated factor (DCAF) were
further discussed. More importantly, given their critical roles
in tumorigenesis, the authors speculated that Cullin 4A and
Cullin 4B could be potentially pursued as new targets for cancer
prevention.
Protein kinases such as Akt, MAPK, and IKK are commonly
upregulated and/or activated in a variety of human cancers. The
Hung group summarized recent advances of howthese oncogenic
kinases regulate protein ubiquitination and degradation. They
proposed that protein phosphorylation induced by these kinases
provides a scaffold for the recognition of ubiquitin ligases (E3s),
thereby eliciting protein ubiquitination and degradation. Several
oncogenic proteins, such as β-catenin, MCL-1, and Snail, known
to be regulated by these oncogenic kinases, were also discussed.
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In addition to kinase regulation, ubiquitination can also
orchestrate DDR by controlling protein degradation and non-
proteolytic pathways. DDR triggers serial signaling events that
are involved in DNA damage repair, transcription regulation,
growth arrest, and apoptosis. The Jin group discussed the role
of Cullin/RING ubiquitination ligase 1 (CRL1) and CRL4 in
multiple steps of the DDR by regulating protein stability. The
Yan group further illustrated the role of histone ubiquitina-
tion and deubiquitination in regulating transcription and DDR.
The E3 ligases and deubiquitinating enzymes regulating the his-
tone ubiquitination and deubiquitination processes and DDR are
discussed.
Like protein ubiquitination and phosphorylation, sumoy-
lation is another important post-translational modiﬁcation
that is also critically involved in DDR. Upon DNA damage,
sumoylation of proteins like 53BP1 and BRCA-1 involved in
DDR and DNA repair is induced and may play a role in
DDR by inducing its E3 ligase activity. David Ann and col-
leagues discussed the potential crosstalk between sumoylation
and ubiquitination and speculated that RNF4 may be a crit-
ical E3 ligase that connects the sumoylation and ubiquitina-
tion crosstalk to participate in ATM-mediated signaling and
DDR.
Although ubiquitination is traditionally viewed as a criti-
cal marker targeting proteins for proteasome-dependent degra-
dation, recent studies reveal that it also plays non-proteolytic
functions. K48-linked ubiquitination in general leads to protein
degradation, while K63-linked ubiquitination fails to do so. The
Lin group and colleagues focused on a new type of ubiquitina-
tion called K63-linked ubiquitination and proposed that K63-
linked ubiquitination serves as an important activation mark
for oncogenic kinase activation, thereby contributing to cancer
development. Thus, targeting K63-linked ubiquitination may be
employed for cancer therapy.
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